Asia
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
The new year began with a fairly low level of clinical trial news. Here’s a look.
Biotech growth in China continued at a rapid pace in 2020, despite COVID-19, which emerged from that country to become a global pandemic. Opportunities in China remain good and are expected to continue.
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
Here’s a run-down of some of the most recent collaboration announcements this week.
Morrisville, North Carolina, has reason to hope that it may be the beneficiary of Fujifilm’s next major investment, a $2 Billion USD large-scale cell culture manufacturing site which the company said will be located near one of its current facilities.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business.
With COVID-19 still running rampant across the globe, Moderna announced it will rapidly expand its vaccine manufacturing operations in order to meet demand in the countries where the medication has received emergency authorization.
Researchers with Shenzhen Institutes of Advanced Technology in China used a variety of computational techniques to simulate drug-virus interactions. They then screened 1,906 existing drugs to evaluate which ones might inhibit replication of SARS-CoV-2, the virus that causes COVID-19.
PRESS RELEASES